In line with this, anti-CD19 CAR T cells with an intermediate affinity scFv (Kd of 14 nM) demonstrated higher proliferation and anti-tumor activity in vivo compared to those with a high-affinity CAR (Kd of 0.3 nM) [19]. This evidence concerns the gene CD19 and neoplasm.